Feb 26 |
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
|
Feb 24 |
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
|
Feb 15 |
Johnson & Johnson settles with Alvotech for off-patent Stelara
|
Feb 15 |
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
|
Feb 4 |
Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?
|
Jan 29 |
Evolus, Alvotech gain as Barclays raises to Ovrweight
|
Jan 29 |
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
|